Sustained release paracetamol containing compositions
View Patent ↗A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.
1. A pharmaceutical composition comprising a bilayer tablet having an immediate release phase of paracetamol and a sustained release phase of paracetamol,
the immediate release phase being in one layer and comprising from about 25 to 35% by weight of the total paracetamol; and
the sustained release phase being in the other layer, and the sustained release layer comprising paracetamol comprising from about 65 to 75% by weight of the total paracetamol in admixture with a matrix forming water soluble polymer which is selected from two different viscosities of hydroxypropylmethylcellulose present in an amount from 0.5 to 10% by weight of the sustained release phase and wherein the hydroxypropylmethylcellulose is present as a low viscosity hydroxypropylmethylcellulose and a high viscosity hydroxypropylmethylcellulose in a ratio of about 1:2; said composition comprising from 600 to 700 mg of paracetamol per unit dose and
a pharmaceutically acceptable carrier, characterised in having an in vitro paracetamol dissolution profile (as determined by the USP type III apparatus, reciprocating basket, with 250 ml of 0.1M HCl at 37° C. set at a cycle speed of 15 strokes/min) with the following constraints:
30 to 48% released after 15 minutes
56 to 75% released after 60 minutes
>85% released after 180 minutes.
2. A composition according to claim 1 in which the in vitro dissolution profile
has the following constraints:
35 to 47% released after 15 minutes
58 to 73% released after 60 minutes
>90% released after 180 minutes.
3. A composition according to claim 1 in which the in vitro dissolution profile has the following constraints:
38 to 44% released after 15 minutes
62 to 70% released after 60 minutes
>95% released after 180 minutes.
4. A composition according to claim 1 in which the paracetamol is
present in an amount of 630 to 680 mg per unit dose.
5. A composition according to claim 4 in which the paracetamol is present in an amount of 650 to 667 mg per unit dose.
6. A composition according to claim 1 in which the matrix forming water soluble polymer is present in an amount from 1 to 6% by weight of the sustained release phase.
7. A composition according to claim 6 in which the matrix forming water soluble polymer is present in an amount from 2 to 4% by weight of the sustained release phase.
8. A composition according to claim 1 in which the sustained release phase comprises from 64% by weight of the total paracetamol.
9. A composition according to claim 8 in which the immediate release component comprises about 29% by weight of the total paracetamol.
10. A pharmaceutical composition comprising a bilayer tablet having an immediate release phase and a sustained release phase of paracetamol, the immediate release phase being in one layer and the sustained release phase being in the other layer, said composition comprising from 600 to 700 mg of paracetamol per unit dose, and wherein the sustained release layer comprises a mixture of at least two hydroxypropylmethylcellulose polymers each having a different the first polymer having a low viscosity and the second polymer having a high viscosity and present in a ratio of about 1:2, characterized in having an in vitro paracetamol dissolution profile (as determined by the USP type III apparatus, reciprocating basket, with 250 ml of 0.1M HCl at 37° C. set at a cycle speed of 15 strokes/min) with the following constraints:
30 to 48% released after 15 minutes
56 to 75% released after 60 minutes
>85% released after 180 minutes; and
said composition providing a mean plasma concentration of at least 3 mcg/ml for at least 1.3 hours longer than a 500 mg paracetamol containing immediate release formulation.
11. A composition according to claim 10 in which the in vitro dissolution profile has the following constraints:
35 to 47% released after 15 minutes
58 to 73% released after 60 minutes
>90% released after 180 minutes.
12. A composition according to claim 10 in which the in vitro dissolution profile has the following constraints:
38 to 44% released after 15 minutes
62 to 70% released after 60 minutes
>95% released after 180 minutes.
13. A composition according to claim 10 in which the paracetamol is present in an amount of 630 to 680 mg per unit dose.
14. A composition according to claim 13 in which the paracetamol is present in an amount of 650 to 667 mg per unit dose.
15. A composition according to claim 10 in which the hydroxypropylmethylcellulose polymers are present in an amount from 0.5 to 10% by weight of the sustained release phase.
16. A composition according to claim 15 in which the hydroxypropylmethylcellulose polymers are in an amount from 1 to 6% by weight of the sustained release phase.
17. A composition according to claim 16 in which the hydroxypropylmethylcellulose polymers are in an amount from 2 to 4% by weight of the sustained release phase.
18. A composition according to claim 16 in which the sustained release phase comprises from 55 to 90% by weight of the total paracetamol, and the immediate release phase comprises from 10 to 45% by weight of the total paracetamol.
19. A composition according to claim 18 in which the sustained release phase comprises from 60 to 80% by weight of the total paracetamol, and the immediate release phase comprises from 20 to 40% by weight of the total paracetamol.
20. A composition according to claim 19 in which the sustained release component comprises from 65 to 75% by weight of the total paracetamol, and the immediate release component comprises from 25 to 35% by weight of the total paracetamol.
21. A pharmaceutical composition, in the form of a bilayer tablet, having an immediate release phase and a sustained release phase of paracetamol,
the immediate release phase being in one layer and the sustained release phase being in the other layer, said composition comprising from 600 to 700 mg of paracetamol per unit dose, and
wherein the sustained release layer comprises a mixture of at least two hydroxypropylmethylcellulose polymers each having a different the first polymer having a low viscosity and the second polymer having a high viscosity and present in a ratio of about 1:2, characterized in having an in vitro paracetamol dissolution profile (as determined by the USP type III apparatus, reciprocating basket, with 250 ml of 0.1M HCl at 37° C. set at a cycle speed of 15 strokes/min) with the following constraints:
30 to 48% released after 15 minutes
56 to 75% released after 60 minutes
>85% released after 180 minutes; and
said composition providing a Cmax which is lower than, and a high Cmin as compared to a 500 mg paracetamol immediate release formulation.
22. A composition according to claim 21 in which the hydroxypropylmethylcellulose polymers are hydroxypropylcellulose is present in an amount from 0.5 to 10% by weight of the sustained release phase.
23. A composition according to claim 22 in which the hydroxypropylmethylcellulose polymers are hydroxypropylcellulose is present in an amount from 1 to 6% by weight of the sustained release phase.
24. A composition according to claim 23 in which the hydroxypropylmethylcellulose polymers are hydroxypropylcellulose is present in an amount from 2 to 4% by weight of the sustained release phase.
25. A composition according to claim 10 in which the sustained release phase comprises from about 65 to 75% by weight of the total paracetamol.
26. A composition according to claim 1 wherein the sustained release phase comprises paracetamol present in an amount of about 64% w/w, high viscosity hydroxypropylmethylcellulose present in an amount of about 2 w/w and low viscosity hydroxypropylmethylcellulose present in an amount of about 1 w/w.
27. A composition according to claim 26 wherein the immediate release phase comprises paracetamol present in an amount of about 29% w/w.